Alpelisib (Piqray®, Novartis, Basel, Switzerland) is a kinase inhibitor that was developed for use in combination with endocrine therapy, specifically fulvestrant, to help overcome endocrine resistance in HR+/HER2− advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.